FIGO and WHF on Menopause Hormone Therapy for Women With Heart Disease Risks
For years, menopause hormone therapy has sat at the centre of a difficult clinical question: can it relieve distressing menopausal symptoms without raising cardiovascular risk? The joint position paper from the International Federation of Gynecology and Obstetrics and the World Heart Federation brings that question into sharper focus, especially for women with hypertension, diabetes, obesity, dyslipidaemia, smoking history, or established ischemic heart disease.
The message is not that hormone therapy is “good” or “bad” for the heart. It is more precise than that. Cardiovascular risk depends on who receives therapy, when it is started, which formulation is used, and why it is prescribed.
For clinicians and patients, the paper supports a shift away from blanket rules. It favours individual risk assessment, careful prescribing, and shared decision-making. For women with heart disease risks, that nuance matters.
Why the FIGO and WHF statement matters
FIGO represents global expertise in gynaecology and women’s health. WHF brings cardiovascular prevention and treatment into the discussion. Their joint position paper is significant because menopause care has often been separated from heart health, even though the two are closely linked.
After menopause, falling oestrogen levels are associated with changes that can affect cardiovascular risk. These include:
Higher LDL cholesterol in many women
Changes in body fat distribution
Greater insulin resistance in some women
Rising blood pressure with age
Increased arterial stiffness
More frequent sleep disruption, which can worsen metabolic health
At the same time, menopause symptoms can be severe. Hot flushes, night sweats, sleep loss, mood changes, genitourinary symptoms, and reduced quality of life can be disabling. For some women, MENOPAUSE HORMONE THERAPY remains the most effective treatment for vasomotor symptoms.
The difficulty comes when symptoms occur in women who already have cardiovascular risk factors, or in those with prior myocardial infarction, angina, coronary artery disease, coronary stenting, or bypass surgery.
The FIGO and WHF paper helps frame the clinical balance. Hormone therapy should not be used to prevent cardiovascular disease. It may still have a role for symptom control in selected women, but the risk profile must be assessed before treatment starts.
The central finding is that timing and baseline risk change the risk profile
One of the most important concepts in current menopause research is the “timing hypothesis”. It suggests that hormone therapy started near the onset of menopause may have a different cardiovascular effect from hormone therapy started many years later.
This idea emerged after reanalysis of large studies, including the Women’s Health Initiative, and from later trials and observational studies. The original WHI results changed practice because they showed increased risks with some hormone therapy regimens, including risks of stroke, venous thromboembolism, and coronary events in certain groups. Later analysis showed that age, time since menopause, and the specific regimen mattered.
In broad terms, evidence suggests:
Women who start systemic hormone therapy before age 60, or within around 10 years of menopause, tend to have a more favourable benefit-risk profile if they are otherwise at low cardiovascular risk.
Women who start therapy later, particularly after age 60 or more than 10 years after menopause, may face higher cardiovascular and thrombotic risks.
Women with established coronary disease need a much more cautious approach.
Hormone therapy should not be prescribed with the goal of preventing heart attacks, stroke, or cardiovascular death.
This does not mean early therapy is automatically safe for everyone. A 52-year-old woman with uncontrolled hypertension, type 2 diabetes, high LDL cholesterol, and active smoking has a different risk profile from a healthy 52-year-old with no major risk factors.
The FIGO and WHF position paper supports this risk-based approach. Age alone is not enough. Time since menopause, symptoms, personal priorities, and cardiovascular history all need to be considered.
Women with cardiovascular risk factors need structured assessment before treatment
For women with risk factors but no known ischaemic heart disease, the paper points towards careful assessment rather than automatic exclusion from therapy.
A useful clinical review usually includes:
Blood pressure measurement
Lipid profile
Blood glucose or HbA1c
Body mass index and waist circumference
Smoking and alcohol history
Family history of premature cardiovascular disease
History of migraine with aura, venous thrombosis, stroke, or liver disease
Current medicines, including antihypertensives, statins, antiplatelet drugs, and diabetes treatment
In India, this point is especially relevant. Cardiometabolic risk can appear at lower body mass index thresholds in South Asian populations. Type 2 diabetes, central obesity, and dyslipidaemia are common, and many women remain underdiagnosed until cardiovascular disease is already advanced.
Risk assessment should not be a one-time formality. If hormone therapy begins, blood pressure, weight, symptoms, bleeding patterns, and cardiovascular risk factors should be reviewed regularly.
The expert consensus is clear: hormone therapy is a treatment for menopausal symptoms, not a substitute for cardiovascular prevention.
That means lifestyle measures and risk-factor treatment remain central. Stopping tobacco, treating hypertension, controlling diabetes, using statins when indicated, improving sleep, and increasing physical activity can reduce cardiovascular risk in ways hormone therapy cannot.
Established ischemic heart disease changes the conversation
Women with established ischemic heart disease form the highest concern group in this discussion. This includes women with previous heart attack, chronic stable angina, coronary artery disease on angiography, coronary stents, coronary bypass surgery, or documented myocardial ischaemia.
For this group, systemic hormone therapy is generally not started for cardiovascular reasons and is usually avoided unless the symptoms are severe, alternatives have failed, and specialist review supports a carefully chosen plan.
The concern is not theoretical. In women with existing coronary disease, several mechanisms may raise risk:
Oral oestrogen can increase clotting factors and venous thromboembolism risk.
Some regimens may increase stroke risk.
Plaque instability and thrombosis are greater concerns in established coronary disease.
Older age and longer time since menopause often overlap with existing heart disease.
Many women in this group have other risks, such as diabetes or hypertension.
For women with recent myocardial infarction, unstable angina, recent stroke, active venous thromboembolism, or uncontrolled hypertension, systemic hormone therapy is usually considered inappropriate. In stable disease, decisions are more individual, but they should involve both menopause expertise and cardiology input.
This is where the FIGO and WHF collaboration is particularly valuable. It signals that gynaecologists and cardiologists need to work together rather than treating menopause symptoms and heart disease as separate problems.
Route, dose, and formulation matter
The position paper aligns with a growing evidence base showing that all hormone therapy is not the same. The cardiovascular and thrombotic profile differs by route, dose, and progestogen type.
Oral oestrogen has more effect on the liver
Oral oestrogen passes through the liver before entering wider circulation. This first-pass effect can increase clotting factors, triglycerides, and inflammatory markers in some women. For women at higher risk of venous thromboembolism or metabolic complications, this matters.
Transdermal oestrogen may be preferable in higher-risk women
Transdermal oestrogen, delivered through a patch, gel, or spray, avoids much of the first-pass liver effect. Observational research suggests it may be associated with a lower risk of venous thromboembolism than oral oestrogen, especially at lower doses.
This does not make it risk-free. It may be a safer option for carefully selected women with risk factors, but it still needs medical supervision.
Progestogen choice also matters
Women with a uterus need endometrial protection if they use systemic oestrogen. This usually means adding a progestogen or using an intrauterine system in some cases.
Some evidence suggests micronised progesterone and dydrogesterone may have a more neutral metabolic and vascular profile than certain synthetic progestins. The choice must also account for bleeding patterns, breast symptoms, availability, cost, tolerability, and cancer risk profile.
Lowest effective dose is the safer principle
The joint paper supports using the lowest effective dose for symptom relief, with regular review. This reduces unnecessary exposure while preserving benefit for women who genuinely need treatment.
Potential benefits are real, but they are symptom-focused
For appropriately selected women, hormone therapy can meaningfully improve quality of life. Benefits may include:
Fewer hot flushes and night sweats
Better sleep when symptoms are disrupting rest
Improved mood and daily functioning in some women
Relief of genitourinary symptoms with local therapy
Prevention of bone loss while treatment continues
The strongest indication remains bothersome vasomotor symptoms. Hormone therapy can also help premature ovarian insufficiency and early menopause, where replacing hormones until the usual age of menopause often has a different risk-benefit profile from starting therapy later in life.
For women with cardiovascular risk factors, these benefits should be weighed against baseline risk. A woman with well-controlled hypertension and severe hot flushes may be considered differently from a woman with uncontrolled blood pressure and a past stroke.
For women with established ischemic heart disease, the threshold is higher. Non-hormonal options should usually be tried first, unless symptoms are severe and specialist assessment supports treatment.
The risks that need direct discussion
A professional consultation should discuss absolute risk, not just relative risk. A small relative increase may mean little for a low-risk woman but much more for someone with established coronary disease.
Key risks include:
Venous thromboembolism
Systemic hormone therapy, especially oral oestrogen, can increase the risk of deep vein thrombosis and pulmonary embolism. Risk is higher in women with obesity, inherited clotting disorders, previous thrombosis, prolonged immobility, or smoking.
Stroke
Some studies have linked systemic hormone therapy, particularly oral therapy in older women, with increased stroke risk. Blood pressure control is critical before treatment.
Coronary events
Hormone therapy should not be used for secondary prevention of coronary disease. In women with established ischemic heart disease, starting systemic therapy may carry higher risk, particularly if disease is unstable or menopause occurred many years earlier.
Breast cancer
Breast cancer risk depends on the type and duration of therapy. Combined oestrogen-progestogen therapy has different implications from oestrogen-only therapy in women who have had a hysterectomy. This risk is not the main focus of the FIGO-WHF cardiovascular discussion, but it remains part of informed consent.
Abnormal bleeding
Unexpected bleeding after menopause needs evaluation. Hormone therapy can cause bleeding, especially early in treatment, but it should not be dismissed without clinical judgement.
What recent research adds to the position paper
Recent research has moved the field away from the simple conclusion that hormone therapy is uniformly dangerous. The better reading is more specific.
Large randomised trials such as the WHI remain central because they identified important harms in certain groups. Later analyses helped clarify that age and time since menopause influence outcomes. Trials such as KEEPS and ELITE added insight into early menopause treatment, vascular markers, and progression of atherosclerosis, although they were not designed to prove reductions in heart attacks or deaths.
Observational studies have also shaped current thinking on transdermal therapy and progestogen choice. These studies cannot prove cause and effect as strongly as randomised trials, but they offer useful signals, especially when results are biologically plausible and consistent across datasets.
Expert groups in menopause medicine and cardiology now tend to agree on several points:
Hormone therapy is effective for vasomotor symptoms.
It should not be prescribed to prevent cardiovascular disease.
Starting therapy near menopause in low-risk women appears to have a more favourable profile than starting it later.
Women with established cardiovascular disease need specialist, individualised assessment.
Route and formulation influence risk.
The FIGO and WHF paper brings these points into a global women’s heart health frame, which is valuable because menopause care often varies widely between countries and health systems.
Practical recommendations for women with risk factors
The most useful recommendations can be summarised in plain terms.
Clinical situation | Practical approach |
Low cardiovascular risk, under 60, within about 10 years of menopause | Hormone therapy may be considered for significant symptoms after counselling |
Cardiovascular risk factors but no known coronary disease | Assess and treat risk factors first, then consider lower-dose and often transdermal options if benefits justify use |
Established ischemic heart disease | Avoid routine systemic hormone therapy, involve cardiology and menopause specialists if symptoms are severe |
Recent heart attack, stroke, blood clot, or unstable angina | Systemic hormone therapy is usually inappropriate |
Genitourinary symptoms without hot flushes | Local vaginal therapy may be considered, as systemic exposure is low |
Desire to prevent heart disease | Use proven cardiovascular prevention, not hormone therapy |
Non-hormonal options also deserve attention. Certain antidepressants at low doses, gabapentin, clonidine, and newer non-hormonal treatments may help vasomotor symptoms in selected women. Cognitive behavioural therapy, weight management, cooling strategies, and sleep interventions can also support symptom control, though they may not be enough for everyone.
For vaginal dryness, painful sex, or recurrent urinary symptoms linked to genitourinary syndrome of menopause, local vaginal oestrogen or non-hormonal moisturisers may be safer and more targeted than systemic therapy for many women. Women with complex cardiovascular histories should still seek medical advice before starting any treatment.
Where shared decision-making becomes essential
The FIGO and WHF position paper does not remove uncertainty. It asks clinicians to handle it better.
A good consultation should answer four questions:
How severe are the symptoms?
What is the woman’s baseline cardiovascular risk?
Are there safer non-hormonal or local options?
If systemic therapy is used, what is the safest route, dose, and duration?
For women with risk factors, cardiovascular prevention should happen alongside symptom care. For women with established ischemic heart disease, the decision should be more cautious, documented, and reviewed.
This content is for general information only and is not a substitute for medical advice. Hormone therapy decisions should be made with a qualified clinician who can review personal risk factors, examination findings, and investigation results.
The takeaway
The joint FIGO and WHF position paper offers a balanced message: menopause symptoms deserve serious treatment, but heart risk cannot be ignored.
For women with cardiovascular risk factors, hormone therapy may still be an option when symptoms are significant and risks are assessed and controlled. For women with established ischemic heart disease, systemic therapy is generally not routine and should only be considered with specialist input when the expected benefit is compelling.
The clearest advice is also the most practical. Treat menopause and cardiovascular health together. Use hormone therapy for the right indication, in the right patient, at the lowest effective dose, and with regular review. That approach respects both quality of life and long-term heart health.
Comments